sodium-oxybate and Nervous-System-Diseases

sodium-oxybate has been researched along with Nervous-System-Diseases* in 4 studies

Reviews

1 review(s) available for sodium-oxybate and Nervous-System-Diseases

Article	Year
GABA, gamma-hydroxybutyric acid, and neurological disease. Annals of neurology, 2003, Volume: 54 Suppl 6 gamma-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABA is converted from glutamic acid by the action of glutamic acid decarboxylase (GAD) of which two isoforms exist GAD65 and GAD67. GABA then is broken down, both within the cell and in the synaptic cleft by GABA transaminase to form succinic semialdehyde. In turn, succinic semialdehyde is converted either to succinic acid by succinic semialdehyde dehydrogenase or into gamma-hydroxybutyric acid (GHB) by succinic semialdehyde reductase. Because GABA modulates the majority of inhibition that is ongoing in the brain, perturbations in GABAergic inhibition have the potential to result in seizures. Therefore, the most common disorder in which GABA is targeted as a treatment is epilepsy. However, other disorders such as psychiatric disease, spasticity, and stiff-person syndrome all have been related to disorders of GABAergic function in the brain. This review covers the roles of GABAergic neurotransmission in epilepsy, anxiety disorders, schizophrenia, stiff-person syndrome, and premenstrual dysphoric disorder. In the final section of this review, the GABA metabolite GHB is discussed in terms of its physiological significance and its role in epilepsy, sleep disorders, drug and alcohol addiction, and an inborn error of GABA metabolism, succinic semialdehyde dehydrogenase deficiency. Topics: Aldehyde Oxidoreductases; Animals; gamma-Aminobutyric Acid; Humans; Mice; Nervous System Diseases; Receptors, GABA-A; Receptors, GABA-B; Sodium Oxybate; Succinate-Semialdehyde Dehydrogenase	2003

Article

Year

GABA, gamma-hydroxybutyric acid, and neurological disease.

Annals of neurology, 2003, Volume: 54 Suppl 6

gamma-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABA is converted from glutamic acid by the action of glutamic acid decarboxylase (GAD) of which two isoforms exist GAD65 and GAD67. GABA then is broken down, both within the cell and in the synaptic cleft by GABA transaminase to form succinic semialdehyde. In turn, succinic semialdehyde is converted either to succinic acid by succinic semialdehyde dehydrogenase or into gamma-hydroxybutyric acid (GHB) by succinic semialdehyde reductase. Because GABA modulates the majority of inhibition that is ongoing in the brain, perturbations in GABAergic inhibition have the potential to result in seizures. Therefore, the most common disorder in which GABA is targeted as a treatment is epilepsy. However, other disorders such as psychiatric disease, spasticity, and stiff-person syndrome all have been related to disorders of GABAergic function in the brain. This review covers the roles of GABAergic neurotransmission in epilepsy, anxiety disorders, schizophrenia, stiff-person syndrome, and premenstrual dysphoric disorder. In the final section of this review, the GABA metabolite GHB is discussed in terms of its physiological significance and its role in epilepsy, sleep disorders, drug and alcohol addiction, and an inborn error of GABA metabolism, succinic semialdehyde dehydrogenase deficiency.

Topics: Aldehyde Oxidoreductases; Animals; gamma-Aminobutyric Acid; Humans; Mice; Nervous System Diseases; Receptors, GABA-A; Receptors, GABA-B; Sodium Oxybate; Succinate-Semialdehyde Dehydrogenase

2003

Other Studies

3 other study(ies) available for sodium-oxybate and Nervous-System-Diseases

Article	Year
Cellular and molecular mechanisms of drugs of abuse and neurotoxicity: cocaine, GHB, and substituted amphetamines. Proceedings of a meeting. August 16-19, 2005. Venice, Italy. Annals of the New York Academy of Sciences, 2006, Volume: 1074 Topics: Amphetamines; Animals; Cocaine; Humans; Illicit Drugs; Nervous System Diseases; Sodium Oxybate	2006
4-Hydroxybutyric aciduria: clinical findings and vigabatrin therapy. Journal of inherited metabolic disease, 1993, Volume: 16, Issue:3 Topics: Aldehyde Oxidoreductases; Anticonvulsants; Child; Female; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Humans; Metabolism, Inborn Errors; Nervous System Diseases; Phenotype; Sodium Oxybate; Spectrometry, Fluorescence; Succinate-Semialdehyde Dehydrogenase; Vigabatrin	1993
Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clinica chimica acta; international journal of clinical chemistry, 1981, Apr-09, Volume: 111, Issue:2-3 Topics: Fatty Acids, Nonesterified; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Humans; Hydroxybutyrate Dehydrogenase; Hydroxybutyrates; Infant; Male; Nervous System Diseases; Sodium Oxybate	1981